#oxidative phosphorylation

[biology-geology-beaches-india]

The Scientific Research Notes of S. Sunkavally. Years: 1986 - 1990.

Page 100.

[nineinch-ninch]

what they dont tell you about AP biology or cell bio or learning about codons is that it fucking Haunts You. everythinf is codon. oh this is just like my guy nadh from oxidative phosphorylation

[blueoaknx]

Mitochondrial Dysfunction in Cardiovascular Disease

 Introduction

Mitochondria are essential organelles responsible for the production of cellular energy in the form of adenosine triphosphate (ATP) through oxidative phosphorylation (OXPHOS). The heart, due to its continuous contractile activity, has a high energy demand and is critically dependent on mitochondrial function for normal physiological and pathological processes. Mitochondrial dysfunction has emerged as a central mechanism in the pathogenesis of cardiovascular diseases (CVDs), including ischemic heart disease, heart failure, hypertension, and arrhythmias. This technical overview discusses the molecular mechanisms of mitochondrial dysfunction in cardiovascular disease, its impact on cellular and organ function, and the potential therapeutic strategies to mitigate mitochondrial-related pathophysiology in CVDs.

Mitochondrial Function in Cardiovascular Cells

Mitochondria are highly dynamic organelles that perform several key functions crucial for the health of cardiovascular cells. They are involved in:

ATP Production via Oxidative Phosphorylation: In the mitochondria, energy production is driven by the electron transport chain (ETC), which is composed of complex I-IV embedded in the inner mitochondrial membrane. Electrons derived from NADH and FADH2 produced during the citric acid cycle are transferred through these complexes to ultimately reduce oxygen to water at complex IV. This electron transfer drives proton pumps that create an electrochemical gradient (proton motive force) across the inner mitochondrial membrane, which is utilized by ATP synthase (complex V) to produce ATP.

Calcium Homeostasis: Mitochondria play a crucial role in buffering intracellular calcium concentrations. They take up calcium from the cytoplasm in response to cellular signaling and help maintain cellular homeostasis by storing calcium in the matrix and releasing it when required for cellular signaling. Dysregulation of mitochondrial calcium handling can lead to pathophysiological conditions such as mitochondrial permeability transition (MPT) and cell death.

Reactive Oxygen Species (ROS) Production: Mitochondria are the primary source of ROS due to the incomplete reduction of oxygen molecules during electron transport in the ETC. Under normal conditions, low levels of ROS act as signaling molecules. However, excessive ROS generation due to mitochondrial dysfunction can cause oxidative stress, which damages cellular components such as lipids, proteins, and mitochondrial DNA (mtDNA), contributing to the pathogenesis of cardiovascular diseases.

Apoptosis and Cell Death: Mitochondria are central regulators of apoptosis. The release of pro-apoptotic factors such as cytochrome c from the mitochondrial intermembrane space into the cytoplasm triggers caspase activation, leading to programmed cell death. Mitochondrial dysfunction in cardiovascular tissues can lead to inappropriate cell death, contributing to the progression of CVDs.

Molecular Mechanisms of Mitochondrial Dysfunction in Cardiovascular Disease

Mitochondrial dysfunction in cardiovascular disease can result from several factors, including oxidative damage, altered mitochondrial dynamics, mutations in mitochondrial DNA, and defects in mitochondrial signaling. Below are the primary molecular mechanisms contributing to mitochondrial dysfunction in cardiovascular pathologies:

1. Oxidative Stress and ROS Accumulation

Excessive ROS generation is a hallmark of mitochondrial dysfunction and a major contributor to cardiovascular disease progression. Under normal conditions, the ETC produces ROS as a byproduct of electron transfer; however, under pathological conditions such as ischemia, hypoxia, or heart failure, there is an increase in mitochondrial ROS production. This increase is due to the altered electron flow through the ETC, particularly at complex I and III, which results in the incomplete reduction of oxygen.

The accumulation of ROS causes oxidative damage to mitochondrial lipids, proteins, and mtDNA. For instance, lipid peroxidation of mitochondrial membranes leads to membrane destabilization and disruption of mitochondrial function. ROS also modify proteins involved in mitochondrial dynamics and bioenergetics, impairing the capacity of mitochondria to generate ATP. Furthermore, oxidative damage to mtDNA leads to mutations that compromise the mitochondrial respiratory chain complexes, creating a vicious cycle of mitochondrial dysfunction.

2. Mitochondrial Permeability Transition (MPT) and Calcium Overload

Mitochondrial permeability transition is a critical event in mitochondrial dysfunction. The opening of the mitochondrial permeability transition pore (mPTP) occurs when the inner mitochondrial membrane becomes permeable to ions and small molecules, disrupting the electrochemical gradient required for ATP production. Under pathological conditions such as ischemia-reperfusion injury, excessive ROS and calcium overload activate the mPTP, leading to mitochondrial swelling, loss of membrane potential, and the release of pro-apoptotic factors (e.g., cytochrome c), triggering cell death.

Calcium overload plays a significant role in mitochondrial dysfunction. During stress conditions like ischemia, excessive intracellular calcium is taken up by mitochondria, causing mitochondrial matrix expansion and rupture of the mitochondrial membrane. This exacerbates cellular injury and promotes cell death pathways in the myocardium, contributing to myocardial infarction and heart failure.

3. Mitochondrial Dynamics Dysregulation

Mitochondrial dynamics refer to the continuous processes of mitochondrial fusion and fission that maintain mitochondrial quality and function. In response to cellular stress, mitochondria can undergo fission to segregate damaged components or fusion to promote functional compensation. Mitochondrial fission is regulated by dynamin-related protein 1 (DRP1), while fusion is mediated by mitofusins (MFN1 and MFN2) and optic atrophy 1 (OPA1). In cardiovascular diseases, this dynamic balance is often disrupted, leading to mitochondrial fragmentation, reduced mitochondrial function, and increased susceptibility to apoptosis.

In heart failure, for example, the upregulation of DRP1 and downregulation of fusion proteins contribute to mitochondrial fragmentation, reduced ATP production, and elevated ROS levels. This dysfunction is exacerbated by altered signaling pathways, including those associated with autophagy (mitophagy), which is responsible for removing damaged mitochondria. Dysfunctional mitophagy further impairs mitochondrial quality control, worsening cardiac injury.

4. Mitochondrial DNA Mutations

Mitochondrial DNA is more prone to mutations than nuclear DNA due to its proximity to the ETC and lack of protective histones. In cardiovascular diseases, mutations in mtDNA contribute to defective mitochondrial function. For example, mutations in genes encoding subunits of the OXPHOS complexes (such as ATP6, ND1, or CYTB) lead to impaired ATP synthesis and defective mitochondrial bioenergetics, contributing to myocardial ischemia and heart failure.

Mitochondrial mutations may also affect the regulation of ROS production and the activation of apoptotic pathways, accelerating tissue damage and organ dysfunction.

Therapeutic Approaches Targeting Mitochondrial Dysfunction in Cardiovascular Disease

Given the critical role of mitochondria in cardiovascular disease, several therapeutic strategies have been developed to target mitochondrial dysfunction and restore normal mitochondrial function. These include:

1. Mitochondrial Antioxidants

Mitochondrial-targeted antioxidants, such as MitoQ, MitoTEMPO, and SkQ1, have been developed to specifically target ROS within mitochondria. These compounds aim to reduce oxidative stress, limit mitochondrial damage, and improve mitochondrial function. Clinical studies are ongoing to assess the efficacy of these antioxidants in reducing myocardial injury and improving outcomes in heart failure and ischemic heart disease.

2. Mitochondrial Biogenesis Activation

Stimulating mitochondrial biogenesis to increase the number of functional mitochondria is another potential therapeutic strategy. Activators of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a key regulator of mitochondrial biogenesis, are being investigated as potential treatments for heart failure. Exercise training is a natural way to activate PGC-1α and increase mitochondrial function, which has been shown to improve cardiac outcomes in patients with heart failure.

3. MPTP Inhibition

Inhibitors of the mPTP, such as cyclosporine A, have been studied for their potential to prevent ischemia-reperfusion injury by inhibiting pore opening. By preserving mitochondrial integrity, these inhibitors may help reduce myocardial damage and improve survival after myocardial infarction.

4. Gene Therapy and Mitochondrial Transplantation

Gene therapy approaches, including the use of CRISPR/Cas9 to correct mitochondrial DNA mutations, hold promise in treating mitochondrial diseases. Additionally, mitochondrial transplantation, where healthy mitochondria are delivered to damaged cardiac cells, is an emerging area of research, with the potential to restore mitochondrial function and improve heart function in patients with severe myocardial injury.

Conclusion

Mitochondrial dysfunction plays a central role in the pathogenesis of cardiovascular diseases, contributing to impaired ATP production, increased ROS production, and cell death. Understanding the molecular mechanisms underlying mitochondrial dysfunction provides critical insights into the development of novel therapeutic strategies. Approaches targeting mitochondrial biogenesis, oxidative stress, mitochondrial dynamics, and mPTP inhibition offer promising avenues for the treatment of cardiovascular diseases and could lead to more effective management of conditions such as heart failure, ischemic heart disease, and hypertension. However, further research and clinical trials are needed to fully elucidate the potential of these therapeutic strategies in improving cardiovascular health.

[biology-geology-beaches-india]

TSRNOSS. Page 174.

[blueoaknx]

The Impact of High Fructose Corn Syrup on Mitochondrial Function

The Impact of High Fructose Corn Syrup on Mitochondrial Function:

Analysis

High fructose corn syrup (HFCS), a widely used sweetener derived from corn, has become a major component of the modern diet, especially in processed foods and sugary beverages. HFCS is composed of glucose and fructose in varying proportions, with HFCS-55 (55% fructose, 45% glucose) and HFCS-42 (42% fructose, 58% glucose) being the most common formulations. While the impact of HFCS on metabolic health has been widely discussed, recent studies have shown that it can also exert a detrimental effect on mitochondrial function. This technical analysis explores the biochemical mechanisms by which HFCS damages mitochondria, contributing to cellular dysfunction and a range of metabolic diseases.

Mitochondrial Physiology and Biochemical Function

Mitochondria are highly specialized organelles responsible for producing adenosine triphosphate (ATP), the primary energy currency of the cell, through oxidative phosphorylation (OXPHOS). This process occurs in the inner mitochondrial membrane and involves the electron transport chain (ETC) and ATP synthase. The mitochondria are also involved in regulating cellular metabolism, maintaining redox balance, calcium homeostasis, and apoptosis (programmed cell death). Mitochondrial dysfunction, characterized by impaired ATP production, altered mitochondrial dynamics (fusion/fission), and excessive reactive oxygen species (ROS) production, is a key factor in the pathogenesis of many chronic diseases, including obesity, insulin resistance, cardiovascular diseases, and neurodegenerative disorders.

Fructose Metabolism and Its Divergence from Glucose

The metabolism of fructose, particularly in the liver, diverges significantly from that of glucose, and it is this divergence that underpins much of the mitochondrial dysfunction associated with HFCS consumption. Unlike glucose, which is predominantly metabolized via glycolysis and the citric acid cycle (TCA cycle), fructose bypasses the rate-limiting step of glycolysis, catalyzed by phosphofructokinase-1 (PFK-1), and is instead phosphorylated by fructokinase to form fructose-1-phosphate. This rapid metabolism of fructose in the liver can overwhelm metabolic pathways and lead to the accumulation of intermediate metabolites such as dihydroxyacetone phosphate (DHAP) and glyceraldehyde, which can be further converted to fatty acids and triglycerides through de novo lipogenesis (DNL).

Excessive fructose consumption leads to the accumulation of triglycerides, particularly within hepatocytes, which is a hallmark of non-alcoholic fatty liver disease (NAFLD). The lipid accumulation in the liver, in turn, exacerbates mitochondrial dysfunction and oxidative stress, contributing to insulin resistance and a cascade of metabolic disorders.

Mechanisms of Mitochondrial Damage Induced by HFCS

Increased ROS Production

One of the most significant consequences of excess fructose metabolism is the elevated production of reactive oxygen species (ROS). ROS are byproducts of cellular respiration, primarily generated at complexes I and III of the electron transport chain. Under normal conditions, mitochondria have a robust antioxidant defense system, including enzymes like superoxide dismutase (SOD), catalase, and glutathione peroxidase, which help neutralize ROS. However, when cells are exposed to an overload of fructose, the liver mitochondria become overwhelmed, leading to excessive ROS generation.

Fructose metabolism increases the NADPH/NADP+ ratio, enhancing the activity of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidases such as NADPH oxidase (NOX), which further amplifies ROS production. These ROS cause oxidative damage to mitochondrial DNA (mtDNA), lipids in the mitochondrial membranes, and mitochondrial proteins. Such damage impairs mitochondrial function by decreasing mitochondrial membrane potential, disrupting the electron transport chain, and promoting mitochondrial fragmentation. Furthermore, mtDNA is particularly vulnerable to ROS due to its proximity to the electron transport chain and the lack of histone protection, leading to mutations that impair mitochondrial replication and protein synthesis.

Disruption of Mitochondrial Biogenesis

Mitochondrial biogenesis refers to the process by which new mitochondria are synthesized within a cell to meet the energy demands. This process is tightly regulated by several transcription factors, most notably peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α). PGC-1α activates the transcription of nuclear and mitochondrial genes involved in energy metabolism, mitochondrial dynamics, and antioxidant defenses.

Fructose consumption has been shown to inhibit PGC-1α expression in both liver and skeletal muscle cells. Reduced PGC-1α levels lead to impaired mitochondrial biogenesis, which limits the ability of cells to adapt to increased energy demands. This is particularly concerning in tissues with high metabolic demands, such as muscle, heart, and liver, where impaired mitochondrial function can exacerbate energy deficits and lead to insulin resistance, fatty liver disease, and other metabolic disorders.

Mitochondrial Permeability Transition and Apoptosis

Chronic exposure to high levels of fructose can lead to mitochondrial permeability transition (MPT), a process in which the mitochondrial inner membrane becomes permeable to ions and small molecules, disrupting mitochondrial function. MPT is typically induced by excessive ROS production, calcium overload, or changes in the mitochondrial membrane potential. The opening of the mitochondrial permeability transition pore (MPTP) leads to the loss of mitochondrial membrane potential, uncoupling of oxidative phosphorylation, and the release of pro-apoptotic factors such as cytochrome c into the cytoplasm. This, in turn, activates the caspase cascade, promoting apoptosis.

In the context of HFCS-induced mitochondrial dysfunction, increased ROS and altered metabolic intermediates, such as ceramides, may trigger MPT and apoptotic pathways, leading to cell death and tissue damage. In tissues such as the liver and pancreas, this can exacerbate the pathological progression of fatty liver disease and insulin resistance.

Fatty Acid Accumulation and Impaired Beta-Oxidation

Excessive fructose consumption induces de novo lipogenesis (DNL) in the liver, leading to an increase in the synthesis of fatty acids, which are esterified into triglycerides and stored within hepatocytes. This accumulation of lipids can overwhelm the capacity of mitochondria to oxidize these fatty acids via beta-oxidation, leading to mitochondrial dysfunction. The accumulation of lipotoxic intermediates such as ceramides and diacylglycerols further impairs mitochondrial function by inhibiting key enzymes involved in mitochondrial energy production.

Moreover, the excess fatty acids can impair mitochondrial membrane fluidity, reducing the efficiency of oxidative phosphorylation. The lipid-induced mitochondrial dysfunction leads to further oxidative stress, creating a feedback loop that exacerbates the metabolic disturbances caused by high fructose intake.

Clinical Implications of HFCS-Induced Mitochondrial Dysfunction

The long-term consumption of HFCS has profound implications for human health, particularly in the context of metabolic diseases:

Insulin Resistance and Type 2 Diabetes: HFCS-induced mitochondrial dysfunction, particularly in liver and muscle cells, contributes to impaired insulin signaling and glucose homeostasis. As mitochondrial function declines, cells become less responsive to insulin, leading to insulin resistance, a precursor to type 2 diabetes.

Non-Alcoholic Fatty Liver Disease (NAFLD): The accumulation of fat in the liver, driven by increased fructose metabolism, leads to mitochondrial damage and dysfunction, which exacerbates the progression of NAFLD to non-alcoholic steatohepatitis (NASH), a more severe form of liver disease.

Cardiovascular Disease: Mitochondrial dysfunction in cardiomyocytes can impair ATP production, leading to reduced contractile function and the progression of cardiovascular disease. The increased oxidative stress and inflammatory mediators associated with mitochondrial damage also contribute to vascular injury and atherosclerosis.

Neurodegenerative Diseases: Impaired mitochondrial function in neurons, driven by high fructose intake, may contribute to neurodegenerative diseases such as Alzheimer's and Parkinson's disease, as mitochondria play a critical role in maintaining neuronal health.

Conclusion

High fructose corn syrup exerts a significant impact on mitochondrial function through several interconnected mechanisms. These include the increased production of reactive oxygen species (ROS), inhibition of mitochondrial biogenesis, induction of mitochondrial permeability transition, and the accumulation of toxic lipid intermediates. These disruptions in mitochondrial homeostasis contribute to the development of insulin resistance, non-alcoholic fatty liver disease, and other chronic metabolic diseases. Addressing the widespread consumption of HFCS and reducing dietary fructose intake could be crucial in mitigating mitochondrial dysfunction and preventing associated metabolic disease

[asongoftearsandfandoms]

It is the year of our lord twenty twenty-four, how has no one made a sick remix of Oxidative Phosphorylation (song by Science Groove, 2004)

[cytoscape-publications]

Effect of downregulated citrate synthase on oxidative phosphorylation signaling pathway in HEI-OC1 cells. Xu, et al., Proteome science doi: 10.1186/s12953-022-00196-0.

cytoHubba is available from the Cytoscape App Store.

[lillyofthewoods]

I may just be yelling into the void because none of you are as interested in molecular biology as I am, but I just came across this article and it’s kind of blowing my mind.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016920/

Basically it’s saying that the traditional picture of how energy is obtained through respiration, involving the electron transport chain, is wrong and needs to be scrapped. The traditional picture states that energy comes from the “fuel” molecules used (i.e. glucose) and is transmitted through the electron transport chain to oxygen, the final electron acceptor. Turns out that’s not the case! The energy actually comes from the bond in oxygen molecules being broken, the energy flow is transmitted by the proton gradient, and the final electron acceptor is hydrogen, not oxygen.

Like... y’all. I have been taught the old picture in every biology course I’ve taken. It’s been in every textbook I have on the subject. And it all needs to be thrown out. These people have proved with MATH that the old way can’t possibly be right and doesn’t actually explain anything. Crazy.